Pyrimidines

On June 10, 2015, Wang, Yuwan; Dai, Xiaoxi; Pan, Zhende; Ren, Yanan; Li, Lei; Li, Ying; Weng, Zhifei; Shen, Li published a patent.Recommanded Product: 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate The title of the patent was Preparation method of emulsifiable oleaginous injection containing hydrophilic medicine. And the patent contained the following:

The title emulsifiable oleaginous injection containing hydrophilic medicine is composed of hydrophilic medicine (such as valnemulin hydrochloride, tiamulin fumarate, etc.) 80-200g, poloxamer 188 20-60g, soybean phospholipids 1-5g and injection soybean oil or soybean oil/ethyl oleate to 1L. The preparation method of the emulsifiable oleaginous injection includes sterilizing injection soybean oil by heating, cooling, adding other materials and sand milling. Emulsification of emulsifiable oleaginous injection containing hydrophilic medicine occurs, when the emulsifiable oleaginous injection contacts to water, forming a emulsion or emulsion/oil system, thus reducing the release rate of drug. The emulsifiable oleaginous injection has large drug load, good biocompatibility, good stability and easy preparation method. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Recommanded Product: 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

The Article related to hydrophilic medicine emulsifiable oleaginous injection, Pharmaceuticals: Formulation and Compounding and other aspects.Recommanded Product: 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On October 12, 1976, Alvan, George E.; Holstius, Elvin A. published a patent.Reference of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate The title of the patent was Solution containing trimethoprim, sulfacetamide, and polymyxin. And the patent contained the following:

Ophthalmic solutions for the treatment of microbial (especially bacterial) infections containing sulfacetamide (I) [144-80-9], a trimethoprim salt, and polymyxin salt were reported. E.g., an ophthalmic solution contains I 0.50, trimethoprim hemisulfate [56585-33-2] 0.123 g, polymyxin B sulfate [1405-20-5], 1,200,000 units, thimerosal 0.001, NaCl 0.83 g, and water for injection to 100.00 ml. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Reference of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

The Article related to trimethoprim sulfacetamide polymyxin ophthalmic solution, Pharmaceuticals: Formulation and Compounding and other aspects.Reference of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On July 7, 2010, Dong, Wei; Li, Xiaowen; Sun, Zhiliang published a patent.HPLC of Formula: 23256-42-0 The title of the patent was Long-acting antibacterial medicinal water-in-oil emulsion and its preparation method. And the patent contained the following:

The title emulsion is composed of water phase, oil phase, emulsifying agents and stabilizers. The oil phase is white oil 7# or 15#. The water-phase emulsifying agent is tween 80 and the oil-phase emulsifying agent is span 80. The emulsion is prepared by adding water-phase stabilizer into water at 40-45°, cooling to room temperature, dissolving antibacterial drug, adding tween 80, stirring to obtain water phase, adding 65-130° white oil 7# or 15# into oil-phase stabilizer, stirring, cooling to 50-60°, dissolving span 80, stirring to obtain oil phase, mixing water phase with oil phase, emulsifying and sterilizing. The antibacterial drug can be slowly released from the emulsion. The emulsion may be used as veterinary medicine for preventing and treating animal diseases in breeding field. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).HPLC of Formula: 23256-42-0

The Article related to veterinary antibacterial drug sustained release emulsion, Pharmaceuticals: Formulation and Compounding and other aspects.HPLC of Formula: 23256-42-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On September 21, 2016, Huang, Jing; Xiao, Liping; Jiang, Wen; Wen, Qingqi; Wu, Youlin; Zhou, Shengchang; Shi, Jiancheng; Ai, Chunxiang; Liang, Shiren published a patent.SDS of cas: 23256-42-0 The title of the patent was A pharmaceutical preparation for preventing and treating sow postpartum disease and its making method. And the patent contained the following:

The present invention discloses a pharmaceutical preparation for preventing and treating sow postpartum disease and its making method. The pharmaceutical preparation for preventing and treating sow postpartum disease comprises lincomycin hydrochloride 5-10, ciprofloxacin lactate 2-6, sodium trimethoxy pyrimidine lactate 1-5, Lonicera japonica flowers 8-12, Houttuynia cordata 5-10, Liquidambar formosana infructescence 1-5, maifanite 20-30, fructooligosaccharide 2-5, and citric acid 0.5-2 weight parts. The making method includes the following steps: 1) weighing Lonicera japonica flowers, Houttuynia cordata, Liquidambar formosana infructescence, maifanite, fructooligosaccharide and citric acid, micronizing through 150 mesh; 2) weighing lincomycin hydrochloride, ciprofloxacin lactate and sodium trimethoxy pyrimidine lactate, fully mixing them uniformly; and 3) mixing the products of step 1) and 2). The present invention contains components compatible with each other, and has synergistic effect, and can cause great appetite for postpartum sows, effectively prevent postpartum diseases. decrease the incidence of mastitis, reduce dioestrus and improve sow utilization. The present invention reduces the incidence of piglet yellow-white dysentery, promotes the healthy growth of piglets, adjusts the ecol. balance of intestinal flora and greatly reduces the side effect of antibiotics disrupting the intestinal bacteria group, and has broad application prospects. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).SDS of cas: 23256-42-0

The Article related to pharmaceutical preparation sow postpartum disease making, Pharmaceuticals: Formulation and Compounding and other aspects.SDS of cas: 23256-42-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On February 13, 2013, Wang, Bin published a patent.SDS of cas: 23256-42-0 The title of the patent was Compound veterinary drug for treating poultry colibacillosis of enteritis type. And the patent contained the following:

The drug comprises neomycin sulfate 3.25%, TMP lactate 0.81%, glutamine 10% and glucose as excipient 85.94%. The preparation method consists of pulverizing all materials resp., sieving, and mixing for 25 min. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).SDS of cas: 23256-42-0

The Article related to compound veterinary drug poultry colibacillosis enteritis, Pharmaceuticals: Formulation and Compounding and other aspects.SDS of cas: 23256-42-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On April 24, 2013, Zhou, Qingfu; Liu, Wenli published a patent.Synthetic Route of 23256-42-0 The title of the patent was Compound for erythromycin thiocyanate composition for preventing and curing bacterial and mycoplasma infection in fowls and preparation method thereof. And the patent contained the following:

The invention relates to a compound for erythromycin thiocyanate composition for preventing and curing bacterial and mycoplasma infection in fowls and preparation method thereof. The composition comprises (by weight part): erythromycin thiocyanate 10-15, neomycin sulfate 10-20, trimethoprim lactate 4-7, and anhydrous glucose 58-76. The beneficial effects of the invention include reasonable prescription, simple preparation, obvious curative effect. Clin. application proves that the composition has specific effect on treating bacterial and mycoplasma infection of poultry. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Synthetic Route of 23256-42-0

The Article related to erythromycin thiocyanate bacteria mycoplasma infection fowl, Pharmaceuticals: Formulation and Compounding and other aspects.Synthetic Route of 23256-42-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On August 22, 2012, Ouyang, Wuqing; Zheng, Xingxing; Ouyang, Shenyu published a patent.Computed Properties of 23256-42-0 The title of the patent was Preparation of pharmaceutical nanoemulsion composition containing erythromycin ethylsuccinate used as antibacterial agent. And the patent contained the following:

The title composition with particle size of 1-100 nm contains (by weight%) erythromycin ethylsuccinate 0.2-4, trimethoprim lactate 0.03-1, surfactant 25-38, cosurfactant 2-11, oil 2.5-9.8% and distilled water as balance. The surfactant is Tween-80, RH-40 or EL-40. The cosurfactant is anhydrous ethanol, 1,2-propylene glycol, isopropanol and/or polyethylene glycol 600. The oil is carvacrol, cinnamaldehyde, iso-Pr myristate and/or triacetin. The preparation method comprises the steps of: (1) dissolving erythromycin ethylsuccinate with oil and cosurfactant to obtain a oil phase, (2) dissolving trimethoprim lactate with distilled water to obtain a water phase, and (3) stirring the oil phase and surfactant at room temperature while dripping the water phase, and stirring to obtain clear and transparent solution The inventive nanoemulsion can be used for treating mycoplasma pneumonia, urogenital tract infection, pertussis, skin and soft tissue infection, and respiratory tract infection induced by sensitive organism. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Computed Properties of 23256-42-0

The Article related to erythromycin ethylsuccinate nanoemulsion antibacterial agent, Pharmaceuticals: Formulation and Compounding and other aspects.Computed Properties of 23256-42-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On January 23, 2013, Wang, Lei published a patent.Quality Control of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate The title of the patent was Preparation method of compound oral liquid of neomycin sulfate and its application in treating severe diarrhea of poultry. And the patent contained the following:

The title compound oral liquid comprises neomycin sulfate 8-15, berberine hydrochloride 3-6, trimethoprim lactate 1-3, astragalan for injection 10-20, levamisole hydrochloride 2-4, acetaminophen 5-15 and water for injection 60-80 weight parts. The preparation method consists of adding 2/3 water for injection (60-70°C), adding remaining materials in sequential order, stirring, adding remaining water for injection, filling with nitrogen gas, adding 0.05-0.2% active carbon, decoloring for 20-30 min, filtering off carbon, detecting content and pH value, filtering at 0.45 or 0.6 um, bottling, and sterilizing with 100°C steam for 30 min. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Quality Control of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

The Article related to compound oral liquid neomycin sulfate severe diarrhea poultry, Pharmaceuticals: Formulation and Compounding and other aspects.Quality Control of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On November 5, 2014, Wang, Yuwan; Pan, Zhende; Dai, Xiaoxi; Ren, Yanan; Shen, Li published a patent.Formula: C17H24N4O6 The title of the patent was A preparation method of tulathromycin oily injection. And the patent contained the following:

The invention relates to a preparation method of tulathromycin oily injection with co-solvent, which is glycerol formal/benzyl benzoate/oily medium, wherein the oily medium comprises Et oleate, and iso-Pr myristate, and the formulation also includes hydrogenated castor oil and soy lecithin. The co-solvent can also prepare a compound preparation of tulathromycin and trimethoprim lactate. The preparation has good stability, good physiol. tolerance, and high drug loading coefficient, so that it is an animal-oriented oily injection both good in slow release and controlled release. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Formula: C17H24N4O6

The Article related to tulathromycin oily injection formulation cosolvent antioxidant, Pharmaceuticals: Formulation and Compounding and other aspects.Formula: C17H24N4O6

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On January 8, 2014, Liu, Guilan; Liu, Tuo; Xie, Lingling published a patent.Product Details of 23256-42-0 The title of the patent was Method for preparing soluble powder of sulfanilamide salt and trimethoprim. And the patent contained the following:

The invention relates to method for preparing sulfanilamide salt and trimethoprim soluble powder. The sulfanilamide salt and trimethoprim soluble powder contains sulfanilamide salt 5∼50%, trimethoprim lactate 1∼10, coated dispersant 10∼25% and alk. excipient added to 100%. The preparation method comprises (1) weighing coated dispersant, adding trimethoprim lactate, stirring to mix well to obtain mixture A; and (2) adding sulfanilamide salt to mixture A, adding alk. excipient to 100%, stirring to obtain sulfanilamide salt and trimethoprim soluble powder. Special processing of sulfanilamide salt and trimethoprim can make sulfanilamide salt alk. drug and trimethoprim acidic drug simultaneously disperse uniformly in water, not precipitate within 2 h, and have stable content of active components. The invention is convenient for animal use, has good curative effect, safe and reliable property, good stability, no adverse reaction, compared with premix it has remarkable application advantage. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Product Details of 23256-42-0

The Article related to sulfanilamide trimethoprim soluble powder veterinary antibiotic, Pharmaceuticals: Formulation and Compounding and other aspects.Product Details of 23256-42-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia